Abbott numbers hint at strong AbbVie beginning; Teva's Nuvigil fails bipolar depression trial;

@FiercePharma: Which pharma brands do docs trust most? Advair (GSK), Humira (AbbVie), Enbrel (Amgen/Pfizer) among them, says survey. More | Follow @FiercePharma

 @AlisonBFierce: Protein Sciences uses cells from the ovaries of armyworms to make the active ingredient in Flublok. Story | Follow @AlisonBFierce

> Abbott Laboratories' ($ABT) fourth-quarter results offer optimism for the success of its newly spun-off pharma unit, AbbVie ($ABBV); lead product Humira saw a 23% sales gain, and other brands performed well. Report

> Nuvigil, the wakefulness drug from Teva Pharmaceutical Industries ($TEVA), failed its second trial in patients with bipolar depression, after hitting goal in its first depression trial. Report

> French drugmaker Pierre Fabre failed to persuade U.K. gatekeepers that its drug Javior is cost-effective as a bladder cancer treatment. Report

> Massachusetts is reviewing its policy on generic drug substitution to prepare for biosimilar versions of biotech drugs. Report

> India's pharma market is expected to grow at 14% to 17% annually through 2016, putting it among the top 5 emerging drug markets. Report

> Amgen ($AMGN) is one of the U.S. companies that is keeping cash declared as "indefinitely invested" overseas in U.S. bank accounts. Report (sub. req.)

Medical Device News

 @FierceMedDev: Quest posts 24% Q4 profit drop amid restructuring. More | Follow @FierceMedDev

 @DamianFierce: $JNJ knew about hip implant failure concerns two years before recalling the all-metal devices. News | Follow @DamianFierce

> Abbott faces slumping stent sales in drug-free future. Report

> After FDA ban, Hospira creeps back into the infusion game with Q Core deal. Story

Biotech News

 @FierceBiotech: Allergan bags migraine drug in $1B MAP Pharma buyout. More | Follow @FierceBiotech

@JohnCFierce: Hugin's bold promises on future Celgene revenue face first test with Abraxane pancreatic cancer OS data. News | Follow @JohnCFierce

@RyanMFierce: I'm thinking, at best, Jimenez and Reinhardt are frienemies. Should be interesting to see how this pharma marriage goes. | Follow @RyanMFierce

> Novartis dumps a long-faded $500M pact with Cytos. Story

> Watson beefs up R&D effort with $305M women's health buyout. Report

Drug Delivery News

> Amunix hooks Janssen with its XTEN delivery technology. Story

> Study: Biotronik's dissolving stent deemed safe, falls short of Abbott's Absorb. Article

> Phosphagenics' oxymorphone pain patch close to clinic. Report

> Nanosphere foam delivers drugs to the bladder. News

Biomarkers News

> Researcher spotlights new biomarker for gliomas. Item

> U.K.-based International Diagnostics Centre brings global diagnostics R&D together. Story

> Bill Gates added to investor list in backing genomic tests startup. Report

> Onconova teams with GVK to take cancer biomarkers to IND phase. News

And Finally... Can a dieticians' trade group be objective about nutrition when it's sponsored by Big Food? Report (sub. req.)

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.